Results 21 to 30 of about 12,890,416 (254)

Gastrointestinal disorders as immune-related adverse events

Exploration of Targeted Anti-tumor Therapy, 2021
Immune checkpoint inhibitors, such as cytotoxic T-lymphocyte antigen 4 inhibitors, programmed cell death 1 inhibitors and programmed cell death-ligand 1 inhibitors, have recently emerged as novel drugs in the anti-cancer therapy.
Daniele Balducci, Claudia Quatraccioni, Antonio Benedetti, Marco Marzioni, Luca Maroni   +4 more
doaj   +1 more source

Immune-related adverse events: A bibliometric analysis

Frontiers in Immunology, 2022
BackgroundDespite providing clinical benefit, immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) in a number of patients.
Shi-Tao Jiang, Yao-Ge Liu, Lei Zhang, Xin-Ting Sang, Yi-Yao Xu, Xin Lu   +5 more
doaj   +1 more source

Immune checkpoint inhibitors⁃related nervous system adverse events

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
Immune checkpoint inhibitors (ICIs) have been widely used in tumor treatment. Immune⁃related adverse events (irAEs) are common in skin, endocrine, gastrointestinal tract, liver and cardiovascular system symptoms.
WANG Ze⁃yi, LIU Guang⁃zhi
doaj   +1 more source

Immune-related adverse events.

, 2022
Immune-related adverse events.
Yuji Miyoshi (3172629), Shohei Iwata (13883584), Junko Nishiguchi (13883590), Masato Kano (13883581), Takeshi Azuma (153452), Sachi Honda (13883587)   +5 more
core   +1 more source

Patterns of immune-related adverse events in patients treated with immune checkpoint inhibitors: a Brazilian real-world analysis

, 2022
Objectives: To report real-world data of a cohort of patients treated with immune-checkpoint inhibitors in Brazil, with focus in immune-related adverse events.
Allan Andersson Lima Pereira, Ana Carolina de Aquino Diniz, Romualdo Barroso-Sousa, Artur Katz, Luiza Nardin Weis, Igor Alexandre Protzner Morbeck, Rodrigo Ramela Munhoz, Maria Paula Furtado Santos, Rodrigo Bovolin de Medeiros, Gustavo dos Santos Fernandes   +9 more
core   +1 more source

Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report

Frontiers in Oncology, 2020
BackgroundImmune checkpoint inhibitors targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed death-1 receptor (PD-1), and programmed death-1 receptor and its ligand (PD-L1) increased the survival of patients affected by metastatic ...
Maria Anna Siciliano, Stefano Dastoli, Stefano Dastoli, Maria d’Apolito, Nicoletta Staropoli, Pierfrancesco Tassone, Pierfrancesco Tassone, Pierosandro Tagliaferri, Pierosandro Tagliaferri, Vito Barbieri   +9 more
doaj   +1 more source

Immune-related adverse events included in the online application.

, 2022
Immune-related adverse events included in the online application.
Ryuji Matsumoto (1992658), Nobuo Shinohara (667646), Ayu Watanabe (6540902), Takahiro Osawa (174382), Hiroshi Kikuchi (2222737), Takashige Abe (7302572), Takafumi Nakao (1550335), Shinji Tanaka (172295), Sachiyo Murai (12245219)   +8 more
core   +1 more source

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

Frontiers in Immunology, 2023
PurposeTo investigate the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and outcomes of ophthalmic irAEs.MethodsWe retrospectively reviewed the medical ...
Linyang Gan, Huan Chen, Xiaowei Liu, Li Zhang   +3 more
doaj   +1 more source

Updated Brazilian guidelines for the management of immune-related adverse events associated with checkpoint inhibitors - edition 2.0

, 2022
Immunotherapy (IT) in the form of monoclonal antibodies targeting coreceptors involved in the modulation of the immune synapse represents a standard of care for patients with distinct malignancies.
Andréia Cristina de Melo, Sergio Jobim de Azevedo, Paulo Marcelo Gehm Hoff, Aknar Calabrich, Rodrigo Ramella Munhoz, Luiza Dib Batista Bugiato Faria, Gilberto de Castro, Guilherme Nader Marta, Antonio Carlos Buzaid, Vladmir Cláudio Cordeiro de Lima, Romualdo Barroso-Sousa, Artur Katz, Guilherme Harada, Carlos Henrique dos Anjos, William Nassib William, Carlos Gil Ferreira, Elimar Elias Gomes, Mariana Laloni, Clarissa Maria de Cerqueira Mathias, Clarissa Baldotto, Alberto Julius Wainstein, Fernando Moura, Gustavo dos Santos Fernandes   +22 more
core   +1 more source

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs

OncoImmunology, 2023
Treatment with immune checkpoint inhibitors (ICIs) has improved the prognosis of melanoma patients. However, ICIs can cause an overactivation of the immune system followed by diverse immunological side effects known as immune-related adverse events (irAE)
Alisa Lepper, Rebekka Bitsch, Feyza Gül Özbay Kurt, Ihor Arkhypov, Samantha Lasser, Jochen Utikal, Viktor Umansky   +6 more
doaj   +1 more source